306 related articles for article (PubMed ID: 18313881)
1. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
Kornmann M; Formentini A; Ette C; Henne-Bruns D; Kron M; Sander S; Baumann W; Kreuser ED; Staib L; Link KH
Eur J Surg Oncol; 2008 Dec; 34(12):1316-21. PubMed ID: 18313881
[TBL] [Abstract][Full Text] [Related]
2. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ
J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725
[TBL] [Abstract][Full Text] [Related]
3. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
[TBL] [Abstract][Full Text] [Related]
4. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
[TBL] [Abstract][Full Text] [Related]
5. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
Schippinger W; Samonigg H; Schaberl-Moser R; Greil R; Thödtmann R; Tschmelitsch J; Jagoditsch M; Steger GG; Jakesz R; Herbst F; Hofbauer F; Rabl H; Wohlmuth P; Gnant M; Thaler J;
Br J Cancer; 2007 Oct; 97(8):1021-7. PubMed ID: 17895886
[TBL] [Abstract][Full Text] [Related]
6. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
Haller DG; Catalano PJ; Macdonald JS; O'Rourke MA; Frontiera MS; Jackson DV; Mayer RJ
J Clin Oncol; 2005 Dec; 23(34):8671-8. PubMed ID: 16314627
[TBL] [Abstract][Full Text] [Related]
7. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
André T; Quinaux E; Louvet C; Colin P; Gamelin E; Bouche O; Achille E; Piedbois P; Tubiana-Mathieu N; Boutan-Laroze A; Flesch M; Lledo G; Raoul Y; Debrix I; Buyse M; de Gramont A
J Clin Oncol; 2007 Aug; 25(24):3732-8. PubMed ID: 17704423
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
Kornmann M; Staib L; Wiegel T; Kron M; Henne-Bruns D; Link KH; Formentini A;
Clin Colorectal Cancer; 2013 Mar; 12(1):54-61. PubMed ID: 23107590
[TBL] [Abstract][Full Text] [Related]
9. Identification of patients with high-risk stage II colon cancer for adjuvant therapy.
Quah HM; Chou JF; Gonen M; Shia J; Schrag D; Landmann RG; Guillem JG; Paty PB; Temple LK; Wong WD; Weiser MR
Dis Colon Rectum; 2008 May; 51(5):503-7. PubMed ID: 18322753
[TBL] [Abstract][Full Text] [Related]
10. Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.
Mori T; Hirota T; Ohashi Y; Kodaira S;
Dis Colon Rectum; 2006 Jul; 49(7):982-92. PubMed ID: 16625329
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
[TBL] [Abstract][Full Text] [Related]
12. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma.
Scheithauer W; Kornek GV; Marczell A; Karner J; Salem G; Greiner R; Burger D; Stöger F; Ritschel J; Kovats E; Vischer HM; Schneeweiss B; Depisch D
Br J Cancer; 1998 Apr; 77(8):1349-54. PubMed ID: 9579845
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant chemotherapy for colon cancer].
Dahl O
Tidsskr Nor Laegeforen; 2007 Nov; 127(23):3094-6. PubMed ID: 18049502
[TBL] [Abstract][Full Text] [Related]
14. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
15. Stratified Survival Analysis After Adjuvant Chemotherapy of Colon Cancer Reveals a Benefit for Older Patients.
Mayer B; Sander S; Paschke S; Henne-Bruns D; Link KH; Kornmann M;
Anticancer Res; 2015 Oct; 35(10):5587-93. PubMed ID: 26408730
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for colon and rectal cancer.
Ratkin GA
Am Fam Physician; 1997 May; 55(7):2487-92, 2495-6. PubMed ID: 9166147
[TBL] [Abstract][Full Text] [Related]
17. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.
Zuckerman IH; Rapp T; Onukwugha E; Davidoff A; Choti MA; Gardner J; Seal B; Mullins CD
J Am Geriatr Soc; 2009 Aug; 57(8):1403-10. PubMed ID: 19563521
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.
Leong CN; Chung HT; Lee KM; Shakespeare TP; Mukherjee RK; Wong LC; Lu JJ; Tey J; Lim R; So JB; Back MF
Cancer J; 2008; 14(4):269-75. PubMed ID: 18677137
[TBL] [Abstract][Full Text] [Related]
19. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer.
Schippinger W; Jagoditsch M; Sorré C; Gnant M; Steger G; Hausmaninger H; Mlineritsch B; Schaberl-Moser R; Mischinger HJ; Hofbauer F; Holzberger P; Mittlböck M; Jakesz R;
Br J Cancer; 2005 May; 92(9):1655-62. PubMed ID: 15856042
[TBL] [Abstract][Full Text] [Related]
20. Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1.
Staib L; Link KH; Beger HG;
J Gastrointest Surg; 2001; 5(3):275-81. PubMed ID: 11419451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]